Given the potential importance in developing inhibitors of ribosome biogenesis to treat aggressive cancers, such as those driven by c‐Myc, it will be critical to understand whether TSC is unique in its response to IMPDH inhibitors or whether it can be more broadly applied to other cancer types. Here, MYC is linked to cancer.